Dataset from A Phase 1b and 2a Study to Assess Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PLX9486 as a Single Agent and in Combination With PLX3397 or Sunitinib (Sutent®) in Patients With Advanced Solid Tumors and Patients With Locally Advanced, Unresectable, or Metastatic Gastrointestinal Stromal Tumor (GIST) Who Have Been Previously Treated With Imatinib Mesylate/KIT-Directed Tyrosine Kinase Inhibitor (TKI) Therapy

The goal of this clinical research study is to learn how CGT9486 (fka PLX9486) may affect
cancer cells with certain mutations in the KIT gene, specifically in participants with types
of advanced solid tumors including gastrointestinal stromal tumor (GIST).

CGT9486 (fka PLX9486) is designed to block KIT gene mutations. These mutations can cause
cancer and cancer cell growth. By blocking these mutations, the drug may kill the cancer
cells with the mutation and/or stop the tumor from growing. By combining CGT9486 (fka
PLX9486) with PLX3397 and CGT9486 (fka PLX9486) with sunitinib, the investigators hope to
block most KIT gene mutations that drive cancer growth.